NCT02089737View on ClinicalTrials.gov

"Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene (All-patient Surveillance)"

CompletedOBSERVATIONAL
Enrollment

3,091

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Advanced or Recurrent Colorectal Cancer
Interventions
DRUG

Panitumumab

Panitumumab for intravenous infusion

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02089737 - "Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene (All-patient Surveillance)" | Biotech Hunter | Biotech Hunter